FDA Delays Authorizing Moderna COVID-19 Shot in Adolescents

The FDA is taking more time to review Moderna’s COVID-19 vaccine in adolescents age 12 to 17 years over concerns the messenger RNA (mRNA)-based shot may be associated with increased risk of myocarditis, a type of heart inflammation.
Source: Drug Industry Daily